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Improvements in clinical pain and experimental
pain sensitivity after cognitive functional therapy in
patients with severe persistent low back pain
Henrik Bjarke Vaegtera,b,*, Kaper Ussingc,d, Jannick Vaaben Johansenc, Irene Stegemejerc,
Thorvaldur Skuli Palssone, Peter O’Sullivanf, Peter Kentf
Abstract
Introduction:Multidisciplinary care is recommended for disabling persistent low back pain (pLBP) nonresponsive to primary care.
Cognitive functional therapy (CFT) is a physiotherapy-led individualised intervention targeting psychological, physical, and lifestyle
barriers to recovery, to self-manage pLBP.
Objectives: This pilot study investigated clinical outcomes and pain thresholds after a 12-weekCFT pathway in patients with severe
pLBP referred to a University Pain Center. Exploratory analyses compared changes in clinical outcomes, opioid consumption, and
costs after CFT with changes after a multidisciplinary pain management (MPM) pathway.
Methods: In total, 47 consecutively referred pLBP patients consented to the CFT pathway. At baseline, 3 and 6 months, clinical
outcomes and PPTs were assessed. Control patients (n 5 99) who had completed an MPM pathway in the last 3 years were
matched from the clinical pain registry used in the Pain Center in a 3:1 ratio based on propensity scores derived from relevant
baseline variables of the CFT cases.
Results: Most clinical outcomes and low back pressure pain threshold were improved at 3 and 6 months after the CFT pathway.
Compared with MPM, CFT patients had significantly larger reductions in disability and improved quality of life after the interventions
at a lower cost (23688€ [confidence interval:23063 to24314€]). Reduction in pain intensity and proportion of patientswithdrawing
from opioids (18.2% vs 27.8%) were similar between CFT and MPM groups.
Conclusion: Improvements in clinical and experimental pain were found after the CFT pathway. Fully powered randomized controlled
trials comparing CFT with an MPM program in patients with disabling pLBP are warranted to control for the current limitations.
Keywords: Low back pain, Persistent pain, Chronic pain, Opioids, Cognitive functional therapy, Multidisciplinary pain rehabilitation
1. Introduction
Low back pain (LBP) is the leading cause of disability.57 Despite
increasing resources being spent on managing this condition,
a significant proportion does not fully recover within a year.11
Failure to recover often results in a trajectory of seeking pain
specialist’s second opinions, surgical evaluations,58 and high use
of opioid medication.21 Evidence suggests that persistent low
back pain (pLBP) is a multidimensional biopsychosocial prob-
lem38,39 with various contributing factors, such as negative pain
cognitions, pain-related fear and emotional distress,27,31,33,55,59
avoidant and protective movement behaviors,10 and unhelpful
lifestyle factors such as activity avoidance and sleep problems.2
Current guidelines recommend that patients with pLBP who
do not benefit from primary care treatment should be referred to
multidisciplinary pain rehabilitation in secondary care settings.6,37
However, such treatments are often expensive, not easily
accessible, and have small effects.16,49 Therefore, less expensive
and more accessible management strategies targeting these
multidimensional barriers to recovery may facilitate earlier
improvements.
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Cognitive functional therapy (CFT)35,36 is a physiotherapy-
led individualised intervention that targets physical, lifestyle,
and psychological barriers to recovery, to coach people to self-
manage pLBP. Cognitive functional therapy has shown
promising results in patients with pLBP in primary care with
low to moderate disability compared with exercise and manual
therapy at 12-month54 and 36-month19 follow-ups. A recent
RCT demonstrated CFT to be more effective in reducing
disability levels at 6 and 12 months, than group education and
exercise in people with moderate disabling pLBP.34 To date,
the effectiveness of CFT has not been investigated in patients
with severe pLBP and high levels of disability who have not
benefited from primary care treatments, and it has not been
compared with a multidisciplinary pain management program
(MPM). Although cognitive and emotional factors, such as
levels of fear and distress, have been observed to reduce after
CFT,35,54 no study has yet investigated whether clinical
improvements after CFT are associated with changes in pain
sensitivity, which would add important knowledge regarding
the possible underlying mechanisms of change associated
with CFT.
As a precursor to a larger-scale randomized controlled trial
comparing CFT with MPM, this pilot study investigated clinical
outcomes and pressure pain thresholds (PPTs) after a 12-week
CFT treatment pathway in patients with severe pLBP referred to
a University Hospital Pain Center. In addition, exploratory
analyses comparing changes in clinical outcomes, opioid
consumption, and treatment costs in patients who took the
CFT pathway with a matched cohort who took the MPM pathway
were performed on clinical outcomes, opioid consumption, and
treatment costs.
It was hypothesized that (1) CFTwould result in improvement in
clinical outcomes and pain sensitivity, and (2) improvements in
clinical pain would be associated with improvements in pain
sensitivity.
2. Materials and methods
The CONSORT-NPT was used as a guideline for reporting this
study,3 which was conducted in accordance with the Helsinki
Declaration, registered at the Danish Data Protection Agency (17/
23847), approved by the local ethics committee (S-20170029),
and all patients provided written informed consent.
2.1. Cognitive functional therapy participants
All patients referred to the Odense University Pain Center
between June 2017 and February 2018, who reported pain (.6
months) in the lower back as their primary pain complaint, were
invited to participate in the study. Patients between 18 and 75
years of age and adept in Danish were eligible. Patients were
excluded if any of these criteria were present: pregnancy, former/
present addictive behavior, neurological, or cardiovascular
diseases. Patients included in the CFT pathway were requested
not to receive other treatments while participating in the study but
were allowed to continue analgesics.
2.2. Case–control patients
The Pain Center care group was retrospectively selected from
250 eligible patients in the PainData Registry used in the Pain
Center, who had LBP, had completed the end of treatment
questionnaire, had received the multidisciplinary intervention
of interest, and had given electronic consent that data could be
used for research. For referral, patients must have had pain.6
months and report significant disability and psychological
distress affecting daily life. Patients in this setting have
moderate to severe pain intensity, high disability, and
psychological distress, and most report pain in more than
one body area.50,52
2.3. Case–control matching
Each person in the CFT group was matched with 3 people in the
Pain Center care group, to account for the potential diversity of
treatment exposure in the control group. Case/control matching
used propensity scores based on the following baseline variables:
age, sex, body mass index, LBP intensity, LBP duration, number
of pain areas, Pain Disability Index (PDI) score, anxiety, de-
pression, pain catastrophization, fear of movement, health-
related quality of life (QOL), and use of analgesics or opioids.
After matching (STATA psmatch2), the distributions of the
baseline variables used in the propensity scoring were not
statistically different (STATA pstest) between the cases and
controls (t tests P 5 0.295–0.957, likelihood-ratio test P 5 0.49,
Rubin R5 1.28), indicating that no selection bias was present on
these measured variables.
2.4. Cognitive functional therapy pathway
The CFT pathway included treatment performed by 1 of 3 CFT-
trained physiotherapists at a private physiotherapy clinic while
patients were on the Pain Center waiting list (approximately 8
months from referral). Each patient received up to 8 consultations
over a period of 3 months. The intervention comprised 3
components: (1) making sense of pain: context-based patient
education focusing on the multidimensional nature of pain and
disability, while reducing the threat of structural damage and
correcting unhelpful beliefs; (2) exposure with control: graded
exposure to painful, feared, or avoided activities with body
relaxation and extinguishing protective behaviours; and (3)
lifestyle changes: patients were encouraged to perform 20 to
30minutes of physical activity daily based on their preference and
taught strategies to manage stress and poor sleep.36
2.5. Control pathway
Treatment at the Pain Center can be diverse, and control patients
were only eligible if they had received a multidisciplinary in-
tervention consisting of a combination of (1) medical treatment
with a specialist pain consultant (ie, individual adjustment of
analgesics to improve effect and reduce side effects) AND (2) one
or more of the following: individual consultations with a pain
psychologist or social worker with cognitive-behavioral therapy
training or participation in a group session with relaxation therapy
or mindfulness, as these represent the most comprehensive
pathway. The Pain Center pathways are based on elements from
cognitive-behavioral therapy, acceptance and commitment
therapy, and mindfulness-based stress reduction programs
(http://www.ouh.dk/wm164091), which have shown moderate
effects in this population and thus have similarities with some of
the CFT components. For this pathway, there was only 1
outcome time point, which was the end of their individualized
treatment. Because this was individualized, the outcome time
point was variable, with a median of 9 months (interquartile
range 3–19).
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2.6. Outcomes
All outcomes were blinded to study participants, physiothera-
pists, and researchers until after the last follow-up.
2.6.1. Pain intensity
Pain intensity was measured using Numerical Pain Rating Scale
(NRS)7 showing good test–retest reliability in patients with chronic
pain.18 Peak and average pain during the past 24 hours were
rated on 2 NRSs ranging from 05 “no pain” to 105 “worst pain
imaginable.”
2.6.2. Pain-related disability
Pain-related disability was assessed with the PDI and the
Oswestry Disability Questionnaire (ODI). The PDI40 is a generic
pain-related disability scale that assesses the degree to which
chronic pain interferes with daily activities. This is constructed
using 11-item NRSs in which 05 “no disability” and 105 “worst
disability.” This study used only the 5 voluntary activities items,
which yielded a 0 to 50 pain-related disability score as previous
psychometric analyses indicated that the obligatory activation
subscale has inadequate internal reliability.45
The ODI14,15 showing good validity and reliability in patients
with low back pain53 is a back pain–specific self-report measure
comprising statements for the patient to select that reflect the
patient’s ability to manage their everyday life despite their pain.
Each item is scored between 0 and 5 with a total score between
0 and 50, and a percentage score is calculated based on the
patients’ total score divided by the total possible score.
2.6.3. Pain-related cognitions and emotions
Catastrophic thinking related to pain was assessed using the
Pain Catastrophizing Scale47 showing acceptable test–retest
reliability and internal consistency in patients with low back
pain.17 The Pain Catastrophizing Scale instructions ask
participants to indicate the degree to which they experienced
each of 13 thoughts or feelings when experiencing pain, on
a 5-point Likert scale with 05 not at all and 45 all the time. The
score is 0 to 52 with a higher score indicating a high level of pain
catastrophizing.
Fear of movement was assessed with the 17-item Tampa
Scale of Kinesiophobia questionnaire25 showing good reliability
and acceptable concurrent validity in patients with low back
pain.48 Each item is rated on a 4-point Likert scale with 1 5
“strongly disagree” and 4 5 “strongly agree” with a higher score
indicating higher levels of fear of movement/kinesiophobia (scale
17–68).
Depression and anxiety was assessed with the Patient Health
Questionnaire-9 (PHQ-9)26 and the Generalized Anxiety
Disorder-7 (GAD-7) questionnaire46 showing good validity and
reliability29,44 and has been widely used to measure depressive
and anxiety symptoms in chronic pain populations.1 Questions
are assessed on a 4-point Likert scale, ranging from 0 5 “not at
all” to 35 “nearly every day” with a higher score indicating higher
depression (scale 0–27) or anxiety (scale 0–21) severity.
Health-related QOL was measured on the 0 to 100 Visual
Analog Scale from the EuroQol 5-D questionnaire with 100
indicating the best QOL.13 Assessment of QOL with the 0 to 100
Visual Analog Scale has shown good correlations with SF-36,
degree of independence, and lower depression scores in patients
with chronic conditions.43
2.6.4. Treatment costs
Treatment costs were calculated accounting for the different
number of sessions for each individual. Calculation of costs for
the CFT intervention was based on the payment rates detailed in
the collective agreement between the Danish Physiotherapy
Association and the Danish regions. Calculation of costs for the
Pain Center care group was based on rates for diagnostic-related
groups (DRG rates) itemized in the collective agreement between
the Danish Government and the Danish regions.
2.6.5. Outcomes available for comparison of the 2 treatment
pathways
In addition to the estimates of treatment costs, the following pain-
related variables were suitable for outcome comparison between
CFT and the Pain Center care pathways: duration of pain, use of
analgesics and opioids, intensity of average clinical pain, pain-
related disability (PDI), body chart (pain drawing) body areas, and
health-related QOL, sex, age, height, and weight.
2.6.6. Assessment of pressure pain sensitivity
Pressure pain thresholds that have shown good within- and
between-session reliability22,51 were assessed by HBV who
was not involved in the CFT pathway. Pressure pain thresholds
were assessed locally at the right erector spinae muscle (3 cm
from the fourth lumbar spinous process) and at the left upper
trapezius muscle (10 cm horizontally from the acromion in
direct line with the seventh cervical spinous process) using
a handheld pressure algometer (Somedic Sales AB, Norra
Mellby, Sweden) with a stimulation area of 1 cm2, and
a pressure rate of 30 kPa/s. Patients were instructed to press
a button when the pressure was perceived as the first sensation
of minimal pain. Two PPT assessments with 20-second
intervals between assessments were completed for each site
and the average used for analysis.
2.7. Statistical analyses
Two stages of analysis were performed, one to describe the
change in the CFT pathway and the second for the comparison of
outcomes between the 2 different pathways.
2.7.1. Analysis 1
Analysis 1 involved, first, describing the number of dropouts from
the CFT pathway and comparing their baseline characteristics
with those that completed the CFT pathway. For continuous
scores, P-values were calculated using independent t tests for
normally distributed variables andMann–WhitneyU tests for non-
normally distributed variables. For categorical scores, P-values
were calculated using x2 tests. Second, themagnitude of change
from baseline to the 3- and 6-month time points was estimated
for those that completed CFT pathway, using paired t tests for
continuous outcomes (Wilcoxon rank-sum tests if not normally
distributed), and the calculation of proportions and odds ratios for
dichotomous outcomes. Finally, the change in PPTs between
baseline and 3 months, and baseline and 6 months were
calculated, and as these data were not normally distributed,
Spearman rho correlations were used to describe the association
between those changes and pain-related disability or pain
intensity at the same outcome time points.
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2.7.2. Analysis 2
Analysis 2 estimated the CFT pathway effect by comparing the
CFT group outcome after treatment with that of Pain Center care
pathway. Between-pathway comparisons in outcomes were
analyzed using linear regression, with adjustment for baseline
scores of the dependent variable. Bootstrapped standard errors
were estimated to adjust for slight departures from normality due
to skew, and 95% confidence intervals were constructed from
those standard errors.
For all analyses of continuous data, when that data were
normally distributed, effects sizes were calculated. For within-
pathway change scores, those effect sizes were standardized
mean changes (SMCs) using a bias-corrected bootstrap
method of 1000 samples with replacement.12 For between-
pathway differences, those effect sizes were standardized
mean differences (SMDs or Cohen’s D) also using a bias-
corrected bootstrap method of 1000 samples with replace-
ment.12 The strength of effect sizes was categorized using
Cohen’s criteria (greater than 0.8 as large, 0.5 as moderate, and
smaller than 0.2 as small).8 The same bootstrap method was
applied for dichotomous data using the Yang and Dalton
method.60
There were few missing data. Across the estimates in
analysis 1, the missingness was 0.8% at baseline, 0.8% at 3
months, and 4.0% at 6 months. Across the estimates in
analysis 2, the missingness for the CFT group was 0.0% at
baseline, 0.6% at 3 months, and 2.5% at 6 months, and for the
Pain Center group was 0.0% at baseline and 3.0% after
treatment. Because of this, and that the analyses were made
with statistical techniques that are unbiased in the presence of
data missing at random, no data were imputed. All statistical
analyses were performed using STATA version 15.1 (Stata-
Corp, College Station, TX) with a P-value of ,0.05 as the
threshold for statistical significance.
3. Results
3.1. Cognitive functional therapy cases
Forty-seven patients consented to participate in the study (Fig. 1
and Table 1). Six patients were excluded after the first session of
CFT, and 7 dropped out within the first 3 CFT sessions due to lack
of motivation or due to other health-related issues being
investigated. Thirty-four patients completed the CFT pathway;
receiving a mean of 6.66 1.3 treatment sessions over 12 weeks
and were included in analysis 1. Most of the patients reported
pain in several areas of the body (Fig. 2). At baseline, the 72.3% of
patients who completed CFT had lower scores on average pain
intensity, pain-related disability, and kinesiophobia compared
with patients who did not complete (Table 1).
3.2. Change in clinical outcomes and pressure pain
thresholds after cognitive functional therapy
In the CFT group, improvements were seen from baseline to end
of treatment in disability, pain intensity, kinesiophobia, pain
catastrophization, anxiety, depression, health-related QOL, and
a reduction in the proportion taking opioids (%). Those effects
were moderate in size, with the point estimates of SMCs ranging
from 0.33 to 0.75. Also, there was an increase in lumbar PPT
(Table 2). At the end of the 3-month treatment period, there was
a moderate-sized association between changes in lumbar PPT
and changes in pain intensity (rs 5 0.340, P 5 0.049; Table 3).
In the CFT group, there were also improvements from baseline
to the 6-month follow-up in disability, health-related QOL,
anxiety, pain catastrophization, depression, kinesiophobia, and
a reduction in the proportion taking opioids. Again, the point
estimates of the SMCs were moderate size, and there continued
to be an increase in lumbar PPT. At 6 months, there were
moderate-sized associations between changes in lumbar PPT
Figure 1. Flow chart.
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and changes in pain-related disability (ODI) scores (rs 5 0.348,
P 5 0.048) and pain intensity (rs 5 0.381, P 5 0.029).
3.3. Comparison between cognitive functional therapy cases
and pain Center care
One of the 34 patients who completed CFT could not be
matched in the propensity score matching. Consequently, 33
CFT cases and 99 matched control cases were included in
analysis 2 (Fig. 2 and Table 4). Pain Center care patients
received amean of 16.46 7.4 treatment sessions over amedian
of 9 months. The treatment period in the Pain Center care
pathway was approximately 3 times longer and 14.7 times the
cost per patient.
Greater reductions in PDI and greater improvements in health-
related QOL were observed for the CFT group, but there were no
differences on all other outcomes (Table 5).
4. Discussion
4.1. Summary of results
This is the first study comparing a CFT pathway to an MPM
pathway for patients with severe and disabling pLBP. While
acknowledging the limitations of the study design of this pilot
case–control study without randomization, the main findings of
this pilot study was significant improvements in pain intensity,
pain-related disability, pain-related cognitions, emotions, QOL,
use of opioids, and back PPT in patients with severe pLBP after
the CFT pathway. In addition, the CFT group had larger
reductions in pain-related disability and improved QOL at
a markedly lower cost at the end of the treatment period
compared with the MPM group.
These findings are potentially important, and somewhat
surprising, given that these patients were nonresponsive to
primary care, and many were taking opioids and on sick leave.
This patient profile is known to be very resistant to change.
Furthermore, they were provided with a relatively small
treatment dose by a single physiotherapist and had no
additional booster sessions outside of the 3-month treatment
period. However, randomized studies with larger samples are
required to reduce the imprecision in many of the estimates of
observed effects and control for the limitations of the study
design.
The observed changes for pain-related disability and psycho-
logical factors are in line with the aim of CFT which directly targets
personally relevant psychological, physical, and lifestyle barriers
to recovery in an individualizedmanner, to return people to valued
activities. These findings are consistent with previous CFT clinical
studies19,35,54 reporting reductions in negative pain cognitions
and emotional distress and improvements in pain coping and
pain self-efficacy.5,35,54 This model of care is aligned to recent
clinical guidelines advocating physical and psychological inter-
ventions in people with high levels of psychological distress.
Typically, this is delivered in a multidisciplinary care environment,
while CFT targets this in an integrated manner delivered by
a single physiotherapist.
In general, the MPM group reported small to modest
improvements in pain intensity, disability, and QOL of a similar
magnitude as recently reported bymultidisciplinary pain centers
in Canada38 and in a large meta-analysis.24 However, the likely
heterogeneity in outcome make these results somewhat
challenging from a cost-effectiveness perspective, as it is
difficult to predict which LBP patients will benefit from an MPM
program.
A novel aspect of this studywas the increase in PPT at the back
after the CFT intervention. Although lower PPT’s have been
reported in peoplewith pLBPand emotional distress,41,42 to date,
no study has reported an increase in PPT at the lower back after
a CFT intervention. The exact underlying mechanism for these
Table 1
Baseline characteristics of the patients consenting to participate in the CFT pathway.
Domain Variable Total (n5 47) Completed CFT (n5 34) Dropouts (n5 13) Mean difference (95% CI) P
Demographic
characteristics
Gender (female) 30 (63.8%) 24 (70.6%) 6 (46.2%) — 0.12*
Marital status (married) 38 (80.9%) 26 (76.5%) 12 (92.3%) — 0.28*
Age (y) 52.1 6 13.2 52.4 6 14.0 51.2 6 11.4 1.3 (27.5 to 10.0) 0.77†
BMI 27.1 6 5.0 27.2 6 4.3 27.0 6 6.7 0.1 (23.2 to 3.4) 0.49‡
Insurance claims 9 (19.1%) 6 (17.6%) 3 (23.1%) — 0.67*
Sick leave (n 5 30) 16 (53.3%) 9 (45.0%) 7 (70.0%) — 0.20*
Pension 17 (36.2%) 14 (41.2%) 3 (23.1%) — 0.52*
Clinical pain characteristics Pain duration (y) 13.5 6 12.6 14.5 6 14.0 10.8 6 7.5 3.7 (24.5 to 12.0) 0.96‡
Peak pain intensity (NRS: 0–10) 7.9 6 1.7 7.7 6 1.8 8.6 6 1.1 20.9 (22.0 to 0.1) 0.08‡
Average pain intensity (NRS: 0–10) 6.4 6 2.0 5.9 6 1.9 7.3 6 1.6 21.3 (22.5 to 20.04) 0.043†
Pain areas (0–71) 17.6 6 15.1 19.4 6 15.4 13.1 6 14.0 6.3 (23.6 to 16.1) 0.16‡
Analgesics 44 (93.6%) 32 (91.4%) 12 (92.3%) — 0.82*
Opioids 30 (63.8%) 20 (58.8%) 10 (76.9%) — 0.25*
Disability (PDI: 0–50) 33.3 6 8.5 31.0 6 8.3 39.4 6 5.8 28.4 (213.5 to 23.3) 0.002†
Disability (Oswestry: 0%–100%) 44.5 6 13.7 41.6 6 13.0 52.1 6 13.1 210.5 (219.0 to 21.9) 0.018†
Psychological
characteristics
Quality of life (EQ5D: VAS 0–100) 44.20 6 23.5 46.1 6 21.4 39.5 6 27.4 6.6 (29.1 to 22.2) 0.40†
Anxiety (GAD-7: 0–21) 6.7 6 5.5 7.0 6 5.5 6.0 6 5.6 1.0 (22.6 to 4.7) 0.54‡
Depression (PHQ-9: 0–27) 10.9 6 5.5 10.9 6 5.9 11.5 6 3.9 20.9 (24.5 to 2.7) 0.61†
Pain catastrophization (PCS: 0–52) 26.2 6 11.2 25.2 6 10.5 28.9 6 12.8 23.8 (211.1 to 3.6) 0.31†
Fear of movement (TSK: 17–68) 41.8 6 8.3 40.2 6 6.7 47.6 6 7.4 28.1 (213.0 to 23.1) 0.002†
Experimental pain sensitivity PPT low back right side (kPa) 228 6 129 225 6 118 238 6 159 217 (299 to 66) 0.75†
PPT upper trapezius (kPa) 197 6 111 212 6 122 156 6 63 56.6 (215 to 128) 0.21‡
* For categorical scores, P-values are based on x2 test.
† For continuous scores, P-values are calculated based on independent t test for normally distributed variables.
‡ For continuous scores, Mann–Whitney U test for non-normally distributed variables.
BMI, body mass index; CFT, cognitive functional therapy; EQ5D, EuroQOL 5-D; GAD-7, Generalised Anxiety Disorder-7; kPa, kiloPascal; NRS, Numeric Pain Rating Scale; PDI, Pain Disability Index; PPT, pressure pain threshold;
Oswestry, Oswestry Disability Index; PCS, Pain Catastrophising Scale; TSK, Tampa Scale of Kinesiophobia; Y/N, yes/no.
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changes are unknown; however, it is known that cognitive
processes and lifestyle factors affect both pain9,20 and pain
sensitivity,32 and it has been hypothesized that reduced fear of
pain and pain-related distress may impact tissue sensitivity.
Interestingly, remote trapezius PPT did not increase, suggesting
that CFT did not cause a generalized change in pain sensitivity,
which point to more local or segmental than systemic mecha-
nisms. Whether these local changes reflect factors such as the
normalization of spinal movement and reduced protective
guarding of the low back, which are key components in the
CFT intervention, is not known. The exact contribution of pain
sensitivity mechanisms to spinal pain is unclear, and it has even
been suggested that pain sensitivity is a poor marker for the
subjective experience of pain and disability.23 Nonetheless, these
preliminary findings of an increase in PPT at the lower back after
CFT intervention and an association with reduced pain intensity
and pain-related disability suggest that changes in pain sensitivity
should be further investigated in studies of CFT.
4.2. Results compared with previous cognitive functional
therapy studies
Comparedwith previous studies investigatingCFT in primary care
patients with low tomoderate disability,19,35,54 the present results
do not display similar large effects on pain, disability, cognitive,
and emotional variables. The findings are in line with a recent RCT
reported moderate and long-term reductions in disability, but not
pain, in people with disabling LBP after CFT comparedwith group
exercise and education.34 Interestingly, CFT has consistently
demonstrated significant long-term effect on fear in previous
studies,5,19,35,54 and fear has been proposed as a potential
mediating effect of disability within the CFT intervention.5 In this
study, the changes in fear were relatively low, which is similar to
recent findings,34 but larger changes in other emotional
constructs, eg, depression and anxiety were seen, indicating
possible different mechanism of change in this complex cohort of
patients. In a recent RCT, CFT resulted in improvements in pain
self-efficacy, risk of chronicity, and pain coping compared with
group education and exercise.34
The explanation for the positive results of CFT in this cohort
may relate to the nature of the intervention. The CFT intervention
targets feared and avoided activities through behavioural experi-
ments that involve exposure to threatening tasks while training
relaxation and abolishing protective and safety behaviours. These
behavioural experiments are specifically designed to challenge
pain-related movement and activity avoidance beliefs and
behaviours.4 Although speculative, this re-engagement with
valued activities coupled with increased pain self-efficacy may
Figure 2. Pain drawings from the 34 patients who completed the cognitive functional therapy pathway.
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Table 2
Change in outcomes in the CFT group from baseline to 1 week after the CFT pathway, and at 6-month follow-up.
Baseline Post-treatment 6-month follow-up
n Mean (SD) n Mean (SD) n Mean (SD)
Oswestry Disability Index
(0–100 low scores better)
34 41.6 (13.0) 34 33.0 (15.6)
Improvement from baseline
20.7% or 28.7 (95% CI 24.4 to
213.0), P , 0.01
SMC 5 0.68 (0.38–1.09)
33 34.9 (18.4)
Improvement from baseline
15.3% or 26.3 (21.47 to 2
11.2), P 5 0.01
SMC 5 0.50 (0.13–0.93)
Pain Disability Index (0–50 low
scores better)
34 31.0 (8.3) 34 24.9 (11.6)
Improvement
19.7% or 26.1 (95% CI 22.7 to
29.4), P , 0.01
SMC 5 0.71 (0.36–1.20)
33 26.4 (12.4)
Improvement
14.6% or 24.5 (20.9 to 28.1),
P , 0.02
SMC 5 0.52 (0.12–0.98)
Low back pain (0–10, low
scores better)
34 5.9 (1.9) 34 4.8 (2.2)
Improvement
18.6% or 21.1 (95% CI 20.5 to
21.7), P , 0.01
SMC 5 0.61 (0.29–1.09)
33 5.2 (2.5)
Improvement
12.5% or 20.8 (20.0 to 21.5),
P 5 0.06
SMC 5 0.40 (0.04–0.85)
Health-related quality of life
(0–100, high scores better)
34 46.1 (21.4) 34 62.0 (19.4)
Improvement
34.5% or 15.9 (95% CI
23.1–8.7), P , 0.01
SMC 5 0.75 (0.42–1.14)
33 61.4 (20.1)
Improvement
32.0% or 14.9 (23.5–6.3), P ,
0.01
SMC 5 0.70 (0.26–1.18)
Generalised Anxiety Disorder
Scale 7 (0–21 low scores
better)
33 7.0 (5.5) 33 5.2 (4.3)
Improvement
25.7% or 21.8 (95% CI 20.5 to
23.2), P , 0.01
SMC 5 0.33 (0.11–0.56)
32 5.1 (5.2)
Improvement
23.9% or 21.6 (20.2 to 23.0),
P , 0.03
SMC 5 0.29 (0.05–0.55)
Pain Catastrophization Scale
(0–52 low scores better)
33 25.2 (10.5) 33 20.8 (10.9)
Improvement
17.5% or 24.3 (95% CI 21.4 to
27.3), P , 0.01
SMC 5 0.41 (0.14–0.68)
32 20.9 (11.8)
Improvement
15.0% or 23.7 (20.7 to 26.7),
P , 0.02
SMC 5 0.35 (0.08–0.63)
Patient Health Questionnaire-9
(depression) (0–27 low scores
better)
33 10.9 (5.9) 33 8.5 (5.9)
Improvement
22.5% or 22.4 (95% CI 20.9 to
23.9), P , 0.01
SMC 5 0.41 (0.15–0.70)
32 8.6 (6.8)
Improvement
17.3% or 21.8 (20.1 to 23.4),
P , 0.02
SMC 5 0.35 (0.06–0.63)
Tampa Scale for Kinesiophobia
(11–44 low scores better)
34 40.2 (6.7) 34 36.7 (6.2)
Improvement
8.7% or 23.5 (95% CI 21.5 to
25.4), P , 0.01
SMC 5 0.51 (0.23–0.86)
32 36.0 (8.0)
Improvement
10.7% or 24.3 (22.1 to 26.5),
P , 0.01
SMC 5 0.64 (0.30–1.03)
Taking opioids (yes/no)
Yes Yes Yes
34 (20) 58.8% 34 (14) 41.2%
Improvement
17.6% (95% CI 4.1% to 31.2%),
P 5 0.01
SMC 5 0.37 (0.12 to 0.70)
33 (15) 45.5%
Improvement
13.3% (2.2% to 28.1%), P ,
0.03
SMC 5 0.28 (0.05 to 0.61)
(continued on next page)
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result in positive effects on mood and emotional status. The
present findings are in line with previous research on manage-
ment of LBP involving exposure treatments.28,56 Interestingly,
patients who did not complete the CFT intervention also showed
higher disability and kinesiophobia than patients who completed
the intervention, which may indicate that they could be the
individuals who might benefit most from CFT core components.
However, not all patients are willing or ready to actively engage in
this treatment approach.
4.3. Limitations
This is a small pilot case–control study without randomization, so
participants were only balanced on the measured variables. The
findings may potentially be influenced by nonspecific effects as
patients receiving CFT were enrolled in a clinical trial, while
patients in the usual MPM group were not. Not all potential
outcome variables were available for control patients, and no
evaluation of other health care services and costs outside of the
study was performed, which could potentially influence the
nondirect treatment-related costs. There was a high dropout rate
in the beginning of the CFT pathway suggesting that the timing of
the pathway was not optimal for all patients or that it did not suit
the expectations of all patients. As participant motivation for
choosing CFT pathway or Pain Center care was not assessed in
this study, we cannot rule out that potential differences may have
inflated the results. Although cases were matched at start of
pathways, the long wait time for usual Pain Center care may have
negative effects across a range of domains including health-
related QOL and psychological well-being.30 Based on the
Table 2 (continued)
Change in outcomes in the CFT group from baseline to 1 week after the CFT pathway, and at 6-month follow-up.
Baseline Post-treatment 6-month follow-up
n Mean (SD) n Mean (SD) n Mean (SD)
Taking analgesia (yes/no)
Yes Yes Yes
34 32 (94.1%) 34 29 (88.2%)
Improvement
5.9% (95% CI26.0% to 17.8%),
P 5 0.32
SMC 5 NP
33 (30) 90.9%
Improvement
3.2% (20.1% to 13.8%),
P 5 0.57
SMC 5 NP
No. of pain areas (0–71)
34 19.4 (15.4) 34 15.7 (11.4)
Improvement
24 (95% CI 27.9 to 0.7),
P 5 0.10
SMC 5 0.26 (20.06 to 0.47)
33 15.8 (12)
Improvement
23.4 (28.1 to 1.7), P 5 0.19
SMC 5 0.22 (20.09 to 0.51)
Baseline Post-treatment 6-month follow-up
n Median (IQR) n Median (IQR) n Median (IQR)
Pressure pain threshold (local
area 5 L5)
34 183.3 (132.5–278.0) 34 230.3 (193.5 to 363.5)
Improvement
33.75 (IQR 20.5 to 130.5),
P 5 0.05
SMC 5 NA
33 257.5 (192.0 to 367.0)
Improvement
55.5 (IQR 26.0 to 128.0),
P 5 0.05
SMC 5 NA
Pressure pain threshold (distal
area 5 upper trapezius)
34 189.5 (121.0–251.0) 34 208.75 (152.0 to 296.5)
Improvement
19.5 (IQR 221.5 to 92.0),
P 5 0.16
SMC 5 NA
32 218.0 (160.5 to 308.0)
Improvement
31.0 (IQR 220.0 to 69.5),
P 5 0.12
SMC 5 NA
CFT, cognitive functional therapy; IQR, interquartile range; NP, a standardised mean change was not calculable in this dichotomous data due to too few improvements; NA, a standardised mean change was not calculable as
these data were not normally distributed; SMC, standardised mean change (mean change/baseline SD).
Table 3
Correlations between change in pressure pain thresholds and change in pain intensity or pain-related disability in the CFT group.
Spearman rho correlations Post-treatment (n 5 34) 6-month follow-up (n 5 33)
Lumbar (local) PPT
Oswestry Disability Index rs5 0.252, (95% CI:20.094 to 0.544) P5 0.150 rs 5 0.348, (95% CI: 0.005 to 0.617) P 5 0.048
Pain Disability Index rs5 0.183, (95% CI:20.165 to 0.491) P5 0.300 rs5 0.284, (95% CI:20.065 to 0.572) P5 0.109
Low back pain intensity rs 5 0.340, (95% CI: 0.002 to 0.61) P 5 0.049 rs 5 0.381, (95% CI: 0.043 to 0.640) P 5 0.029
Trapezius (distal) PPT
Oswestry Disability Index rs5 0.023, (95% CI:20.318 to 0.358) P5 0.897 rs5 0.004, (95% CI:20.340 to 0.347) P5 0.983
Pain Disability Index rs5 0.156, (95% CI:20.192 to 0.470) P5 0.378 rs5 0.173, (95% CI:20.181 to 0.488) P5 0.335
Low back pain intensity rs5 0.253, (95% CI:20.093 to 0.544) P5 0.149 rs5 0.318, (95% CI:20.029 to 0.596) P5 0.072
CI, confidence interval; CFT, cognitive functional therapy; PPT, pressure pain threshold.
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exploratory nature of several of the statistical analyses, we
acknowledge the risk of Type I error.
5. Conclusions
Patients receiving CFT showed significant improvements in
pain intensity, pain-related disability, pain-related cognitions,
emotions, QOL, use of opioids, and PPTs. The CFT pathway
produced superior outcomes for pain-related disability and
QOL at a much lower cost for patients with severe disabling
pLBP compared with an MPM pathway. Although we are
cautious not to over interpret this case–control data, fully
powered RCTs investigating these results in this setting is
warranted, as there is an urgent need to identify alternative,
clinically and cost-effective interventions to help people
manage disabling pLBP.
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Table 4
Baseline characteristics in 33 CFT cases and 99 matched control
patients.
CFT group
(n 5 33)
Pain Center care
group (n 5 99)
Age, mean (SD) 51.9 (13.9) 50.2 (11.3)
Female, n (%) 23 (69.7%) 69 (69.7%)
Height (cm), mean (SD) 171.2 (8.1) 164.8 (48.3)
Weight (kg), mean (SD) 79.8 (14.7) 79.1 (20.6)
Pain duration, % (n)
,1 yr 12.1% (4) 11.1% (11)
2–5 yrs 30.3% (10) 28.3% (28)
6–10 yrs 12.1% (4) 20.2 (20)
.10 yrs 46% (15) 40.4 (40)
Pain Disability Index (PDI: 0–50) 31.1 (10.5) 32.9 (8.9)
Low back pain intensity (NRS: 0–10) 5.9 (1.9) 6.1 (1.7)
Health-related quality of life (EQ5D-VAS:
0–100)
46.1 (21.7) 43.6 (20.1)
Taking opioids (yes) 20 (60.6%) 62 (62.6%)
Taking analgesics (yes) 32 (97.0%) 94 (96.0%)
CFT, cognitive functional therapy; EQ5D5 EuroQOL 5-D; NRS, Numeric Pain Inventory; PDI, Pain Disability
Index; VAS, Visual Analog Scale.
Table 5
Comparisons of outcomes in the CFT and Pain Center care pathways.
CFT Pain Center care Between-group difference
n Mean (SD) n Mean (SD) CFT—usual care (95% CI)
Pain Disability Index (0–50 low scores better)
Baseline 33 31.1 (10.5) 99 32.9 (8.9) 21.8 (25.8 to 2.2), P 5 0.38
After treatment 33 26.2 (8.6) 96 30.8 (7.5) 24.6 (27.6 to 21.7), P , 0.01
SMD 5 0.52 (0.15 to 0.97)
Improvement 15.8% 6.4%
Pain intensity (0–10, low scores better)
Baseline 33 5.9 (1.9) 99 6.1 (1.7) 20.2 (20.9 to 0.6), P 5 0.68
After treatment 33 4.9 (2.0) 99 5.2 (1.7) 20.3 (21.0 to 0.4), P 5 0.45
SMD 5 0.21 (20.15 to 0.66)
Improvement 17.0% 14.8%
Health-related quality of life (0–100, high scores
better)
Baseline 33 46.1 (21.7) 99 43.6 (20.1) 2.5 (25.8 to 19.7), P 5 0.55
After treatment 32 61.2 (17.5) 95 49.5 (21.4) 11.8 (5.4 to 18.1), P , 0.01
SMD 5 0.60 (0.23 to 0.97)
Improvement 32.8% 13.3%
Cost of treatment (Euros)
33 267.90€ (49.61€) 99 3956.19€ (1810.58€) 3688.29€ (CI: 3063 to 4314€), P 5 0.01
Saving 93.2%
Taking opioids (yes/no)
Yes Yes Odds ratio
Baseline 33 20 (60.6%) 99 62 (62.6%) 0.92 (0.41 to 2.1), P 5 0.84
After treatment 33 14 (42.4%) 99 31 (34.8%) 1.35 (0.60 to 3.1), P 5 0.47
SMD 5 20.16 (20.60 to 0.22)
Improvement 18.2% 27.8%
Taking analgesics (yes/no)
Yes Yes Odds ratio
Baseline 33 32 (97.0%) 99 94 (96.0%) 1.70 (0.19 to 15.3), P 5 0.63
After treatment 33 29 (87.9%) 98 88 (89.8%) 0.82 (0.24 to 2.8), P 5 0.76
SMD 5 0.09 (20.52 to 0.84)
Improvement 9.1% 6.2%
CI, confidence interval; CFT, cognitive functional therapy; SMD, standardised mean difference (Cohen’s D).
5 (2019) e802 www.painreportsonline.com 9
Acknowledgements
The authors thank Prof Anne Smith for her statistical and
interpretative advice.
Article history:
Received 20 August 2019
Received in revised form 22 October 2019
Accepted 9 November 2019
References
[1] Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of
depression and anxiety alone and in combination with chronic
musculoskeletal pain in primary care patients. Psychosom Med 2008;
70:890–7.
[2] Bjorck-van Dijken C, Fjellman-Wiklund A, Hildingsson C. Low back pain,
lifestyle factors and physical activity: a population based-study. J Rehabil
Med 2008;40:864–9.
[3] Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT
statement for randomized trials of nonpharmacologic treatments: a 2017
update and a CONSORT extension for nonpharmacologic trial abstracts.
Ann Intern Med 2017;167:40–7.
[4] Bunzli S, McEvoy S, Dankaerts W, O’Sullivan P, O’Sullivan K. Patient
perspectives on participation in cognitive functional therapy for chronic
low back pain. Phys Ther 2016;96:1397–407.
[5] Caneiro JP, Smith A, Linton SJ, Moseley GL, O’Sullivan P. “How does
change unfold?” an evaluation of the process of change in four people
with chronic low back pain and high pain-related fear managed with
cognitive functional therapy: a replicated single-case experimental design
study. Behav Res Ther 2019;117:28–39.
[6] ChouR,Deyo R, Friedly J, Skelly A, Hashimoto R,WeimerM, FuR,Dana T,
Kraegel P, Griffin J, Grusing S, Brodt ED. Nonpharmacologic therapies for
low back pain: a systematic review for an American College of Physicians
Clinical Practice Guideline. Ann Intern Med 2017;166:493–505.
[7] Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain
Inventory. Ann Acad Med Singapore 1994;23:129–38.
[8] Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed.
Hillsdale: Erlbaum, 1988.
[9] Crettaz B, Marziniak M, Willeke P, Young P, Hellhammer D, Stumpf A,
Burgmer M. Stress-induced allodynia—evidence of increased pain
sensitivity in healthy humans and patients with chronic pain after
experimentally induced psychosocial stress. PLoS One 2013;8:e69460.
[10] Dankaerts W, O’Sullivan P, Burnett A, Straker L, Davey P, Gupta R.
Discriminating healthy controls and two clinical subgroups of nonspecific
chronic low back pain patients using trunk muscle activation and
lumbosacral kinematics of postures and movements: a statistical
classification model. Spine (Phila Pa 1976) 2009;34:1610–8.
[11] Dunn KM, Jordan K, Croft PR. Characterizing the course of low back
pain: a latent class analysis. Am J Epidemiol 2006;163:754–61.
[12] Efron B, Tibshirani RJ, An introduction to the bootstrap. New York:
Chapman and Hall, 1993.
[13] EuroQol. EuroQol—a new facility for the measurement of health-related
quality of life. Health Policy 1990;16:199–208.
[14] Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswestry low back
pain disability questionnaire. Physiotherapy 1980;66:271–3.
[15] Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine (Phila Pa
1976) 2000;25:2940–52; discussion 2952.
[16] Fashler SR, Cooper LK, Oosenbrug ED, Burns LC, Razavi S, Goldberg L,
Katz J. Systematic review of multidisciplinary chronic pain treatment
facilities. Pain Res Manag 2016;2016:5960987.
[17] Fernandes L, Storheim K, Lochting I, Grotle M. Cross-cultural adaptation
and validation of the Norwegian pain catastrophizing scale in patients with
low back pain. BMC Musculoskelet Disord 2012;13:111.
[18] Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH.
Reliability of pain scales in the assessment of literate and illiterate patients
with rheumatoid arthritis. J Rheumatol 1990;17:1022–4.
[19] Fersum KV, Smith A, Kvale A, Skouen JS, O’Sullivan P. Cognitive
functional therapy in patients with non specific chronic low back pain A
randomized controlled trial 3-year follow up. Eur J Pain 2019;23:
1416–24.
[20] Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an
update and a path forward. J Pain 2013;14:1539–52.
[21] Gore M, Sadosky A, Stacey BR, Tai KS, Leslie D. The burden of chronic
low back pain: clinical comorbidities, treatment patterns, and health care
costs in usual care settings. Spine (Phila Pa 1976) 2012;37:E668–77.
[22] Graven-Nielsen T, Vaegter HB, Finocchietti S, Handberg G, Arendt-
Nielsen L. Assessment of musculoskeletal pain sensitivity and temporal
summation by cuff pressure algometry: a reliability study. PAIN 2015;156:
2193–202.
[23] Hubscher M, Moloney N, Leaver A, Rebbeck T, McAuley JH, Refshauge
KM. Relationship between quantitative sensory testing and pain or
disability in people with spinal pain-a systematic review and meta-
analysis. PAIN 2013;154:1497–504.
[24] Kamper SJ, Apeldoorn AT, Chiarotto A, Smeets RJ, Ostelo RW, Guzman
J, van Tulder MW. Multidisciplinary biopsychosocial rehabilitation for
chronic low back pain: cochrane systematic review and meta-analysis.
BMJ 2015;350:h444.
[25] Kori SH, Miller RP, Todd DD. Kinisophobia: a new view of chronic pain
behavior. Pain Manag 1990;1:35–43.
[26] Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief
depression severity measure. J Gen Intern Med 2001;16:606–13.
[27] Linton SJ. A review of psychological risk factors in back and neck pain.
Spine (Phila Pa 1976) 2000;25:1148–56.
[28] Linton SJ, BoersmaK, JanssonM,Overmeer T, LindblomK, Vlaeyen JWS.
A randomized controlled trial of exposure in vivo for patientswith spinal pain
reporting fear of work-related activities. Eur J Pain 2008;12:722–30.
[29] Lowe B, Kroenke K, Herzog W, Grafe K. Measuring depression outcome
with a brief self-report instrument: sensitivity to change of the Patient
Health Questionnaire (PHQ-9). J Affect Disord 2004;81:61–6.
[30] Lynch ME, Campbell F, Clark AJ, Dunbar MJ, Goldstein D, Peng P,
Stinson J, Tupper H. A systematic review of the effect of waiting for
treatment for chronic pain. PAIN 2008;136:97–116.
[31] Main CJ, Foster N, Buchbinder R. How important are back pain beliefs
and expectations for satisfactory recovery from back pain? Best Pract
Res Clin Rheumatol 2010;24:205–17.
[32] Meints SM,Mawla I, Napadow V, Kong J, Gerber J, Chan ST,Wasan AD,
Kaptchuk TJ, McDonnell C, Carriere J, Rosen B, Gollub RL, Edwards RR.
The relationship between catastrophizing and altered pain sensitivity in
patients with chronic low-back pain. PAIN 2019;160:833–43.
[33] Meyer K, Tschopp A, Sprott H, Mannion AF. Association between
catastrophizing and self-rated pain and disability in patients with chronic
low back pain. J Rehabil Med 2009;41:620–5.
[34] O’Keeffe M, O’Sullivan P, Purtil H, Bargary N, O’Sullivan K. Cognitive
functional therapy compared with a group-based exercise and education
intervention for chronic low back pain: a multicentre randomised
controlled trial (RCT). BJSM 2019. doi:10.1136/bjsports-2019-100780.
[Epub ahead of print].
[35] O’Sullivan K, Dankaerts W, O’Sullivan L, O’Sullivan PB. Cognitive
functional therapy for disabling nonspecific chronic low back pain:
multiple case-cohort study. Phys Ther 2015;95:1478–88.
[36] O’Sullivan PB, Caneiro JP, O’Keeffe M, Smith A, DankaertsW, Fersum K,
O’Sullivan K. Cognitive functional therapy: an integrated behavioral
approach for the targeted management of disabling low back pain. Phys
Ther 2018;98:408–23.
[37] Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CC, Chenot JF, van
Tulder M, Koes BW. Clinical practice guidelines for the management of
non-specific low back pain in primary care: an updated overview. Eur
Spine J 2018;27:2791–803.
[38] Page MG, Boyd K, Ware MA. Examination of the course of low back pain
intensity based on baseline predictors and health care utilization among
patients treated in multidisciplinary pain clinics: a Quebec Pain Registry
Study. Pain Med 2019;20:564–73.
[39] Pincus T, Kent P, Bronfort G, Loisel P, Pransky G, Hartvigsen J. Twenty-
five years with the biopsychosocial model of low back pain-is it time to
celebrate? A report from the twelfth international forum for primary care
research on low back pain. Spine (Phila Pa 1976) 2013;38:2118–23.
[40] Pollard CA. Preliminary validity study of the pain disability index. Percept
Mot Skills 1984;59:974.
[41] Rabey M, Slater H, O’Sullivan P, Beales D, Smith A. Somatosensory
nociceptive characteristics differentiate subgroups in people with chronic
low back pain: a cluster analysis. PAIN 2015;156:1874–84.
[42] Rabey M, Smith A, Beales D, Slater H, O’Sullivan P. Differing
psychologically derived clusters in people with chronic low back pain
are associated with different multidimensional profiles. Clin J Pain 2016;
32:1015–27.
[43] Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D—a generic quality
of life measure-is a useful instrument to measure quality of life in patients
with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;69:67–73.
[44] Seo JG, Park SP. Validation of the Generalized Anxiety Disorder-7 (GAD-
7) and GAD-2 in patients with migraine. J Headache Pain 2015;16:97.
[45] Soer R, Koke AJ, Vroomen PC, Stegeman P, Smeets RJ, Coppes MH,
Reneman MF. Extensive validation of the pain disability index in 3 groups
10 H.B. Vaegter et al.·5 (2019) e802 PAIN Reports®
of patients with musculoskeletal pain. Spine (Phila Pa 1976) 2013;38:
E562–8.
[46] Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for
assessing generalized anxiety disorder: the GAD-7. Arch Intern Med
2006;166:1092–7.
[47] Sullivan MJ, Bishop SR, Pivik J. The pain catastrophizing scale:
development and validation. Psychol Assess 1995;7:524–32.
[48] Swinkels-Meewisse EJ, Swinkels RA, Verbeek AL, Vlaeyen JW,
Oostendorp RA. Psychometric properties of the Tampa Scale for
kinesiophobia and the fear-avoidance beliefs questionnaire in acute low
back pain. Man Ther 2003;8:29–36.
[49] Thomsen AB, Sorensen J, Sjogren P, Eriksen J. Economic evaluation of
multidisciplinary pain management in chronic pain patients: a qualitative
systematic review. J Pain Symptom Manage 2001;22:688–98.
[50] Vaegter HB, Graven-Nielsen T. Pain modulatory phenotypes differentiate
subgroups with different clinical and experimental pain sensitivity. PAIN
2016;157:1480–8.
[51] Vaegter HB, Handberg G, Graven-Nielsen T, Edwards R. Hypoalgesia
after exericse and cold pressor test are reduced in chronic
musculuskeletal pain patients with high pain sensitivity. Clin J Pain
2015;32:58–69.
[52] Vaegter HB, Handberg G, Kent P. Brief psychological screening
questions can be useful for ruling out psychological conditions in
patients with chronic pain. Clin J Pain 2018;34:113–21.
[53] VianinM. Psychometric properties and clinical usefulness of theOswestry
Disability Index. J Chiropr Med 2008;7:161–3.
[54] Vibe Fersum K, O’Sullivan P, Skouen JS, Smith A, Kvale A. Efficacy of
classification-based cognitive functional therapy in patients with non-
specific chronic low back pain: a randomized controlled trial. Eur J Pain
2013;17:916–28.
[55] Vlaeyen JW, Crombez G. Fear of movement/(re)injury, avoidance and
pain disability in chronic low back pain patients. Man Ther 1999;4:
187–95.
[56] Vlaeyen JW, de Jong J, Geilen M, Heuts PH, van Breukelen G. Graded
exposure in vivo in the treatment of pain-related fear: a replicated single-
case experimental design in four patients with chronic low back pain.
Behav Res Ther 2001;39:151–66.
[57] Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya
K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal
R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews
KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH,
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